NS Partners’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.5M | Sell |
193,233
-706
| -0.4% | -$58.2K | 0.69% | 47 |
|
|
2025
Q4 | $16.5M | Sell |
193,939
-7,273
| -4% | -$597K | 0.65% | 45 |
|
|
2025
Q3 | $15.6M | Sell |
201,212
-89
| -0% | -$6.95K | 0.61% | 50 |
|
|
2025
Q2 | $15.7M | Sell |
201,301
-4,998
| -2% | -$373K | 0.64% | 48 |
|
|
2025
Q1 | $15M | Buy |
206,299
+1,099
| +0.5% | +$78.7K | 0.66% | 51 |
|
|
2024
Q4 | $15.2M | Sell |
205,200
-3,441
| -2% | -$241K | 0.63% | 52 |
|
|
2024
Q3 | $13.8M | Buy |
208,641
+4,170
| +2% | +$303K | 0.58% | 53 |
|
|
2024
Q2 | $18.9M | Buy |
204,471
+756
| +0.4% | +$66.9K | 0.86% | 38 |
|
|
2024
Q1 | $19.5M | Sell |
203,715
-4,027
| -2% | -$338K | 0.9% | 42 |
|
|
2023
Q4 | $15.8M | Buy |
207,742
+352
| +0.2% | +$24.5K | 0.77% | 50 |
|
|
2023
Q3 | $14.4M | Sell |
207,390
-603
| -0.3% | -$48.5K | 0.77% | 51 |
|
|
2023
Q2 | $19.6M | Sell |
207,993
-1,531
| -0.7% | -$133K | 1.03% | 42 |
|
|
2023
Q1 | $17.3M | Buy |
209,524
+402
| +0.2% | +$31.6K | 0.97% | 48 |
|
|
2022
Q4 | $15.6M | Buy |
209,122
+13,334
| +7% | +$1.03M | 0.94% | 51 |
|
|
2022
Q3 | $16.2M | Sell |
195,788
-26,723
| -12% | -$2.57M | 1.05% | 43 |
|
|
2022
Q2 | $21.2M | Buy |
222,511
+36,099
| +19% | +$3.74M | 1.28% | 31 |
|
|
2022
Q1 | $21.9M | Sell |
186,412
-7,496
| -4% | -$841K | 1.17% | 34 |
|
|
2021
Q4 | $25.1M | Buy |
193,908
+618
| +0.3% | +$72.1K | 1.18% | 34 |
|
|
2021
Q3 | $21.9M | Buy |
193,290
+861
| +0.4% | +$98.3K | 1.11% | 41 |
|
|
2021
Q2 | $19.9M | Buy |
192,429
+722
| +0.4% | +$68.1K | 1.05% | 42 |
|
|
2021
Q1 | $16M | Sell |
191,707
-7,802
| -4% | -$660K | 0.93% | 44 |
|
|
2020
Q4 | $18.2M | Buy |
199,509
+1,944
| +1% | +$161K | 1.06% | 40 |
|
|
2020
Q3 | $15.8M | Buy |
197,565
+7,866
| +4% | +$614K | 1.04% | 40 |
|
|
2020
Q2 | $13.1M | Buy |
189,699
+1,014
| +0.5% | +$72.1K | 0.97% | 41 |
|
|
2020
Q1 | $11.9M | Buy |
188,685
+57,273
| +44% | +$4.13M | 1.1% | 36 |
|
|
2019
Q4 | $10.2M | Sell |
131,412
-33
| -0% | -$2.58K | 0.81% | 47 |
|
|
2019
Q3 | $9.63M | Buy |
131,445
+3,786
| +3% | +$266K | 0.87% | 47 |
|
|
2019
Q2 | $7.86M | Buy |
127,659
+25,449
| +25% | +$1.54M | 0.72% | 52 |
|
|
2019
Q1 | $6.52M | Hold |
102,210
| – | – | 0.6% | 60 |
|
|
2018
Q4 | $5.22M | Buy |
102,210
+29,535
| +41% | +$1.49M | 0.56% | 63 |
|
|
2018
Q3 | $4.22M | Buy |
+72,675
| New | +$3.55M | 0.4% | 77 |
|
Other funds holding EW
VCM
VPM
NS Partners's EW Position: Q1 2026 in Review
NS Partners reduced its Edwards Lifesciences (EW) stake by 0.36% in Q1 2026, selling an estimated $58.2K and leaving 193,233 shares worth $15.5M. The position accounts for 0.69% of the portfolio, ranked #47.
NS Partners first reported a position in EW in Q3 2018 and has held it in 31 quarters since. The position peaked at $25.1M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- NS Partners held 193,233 shares of Edwards Lifesciences worth $15.5M as of Q1 2026.
- NS Partners sold 706 Edwards Lifesciences shares in Q1 2026, an estimated $58.2K.
- Edwards Lifesciences made up 0.69% of NS Partners's portfolio in Q1 2026, its #47 holding.
- NS Partners first reported a position in Edwards Lifesciences in Q3 2018 and has held it in 31 quarters since.
- NS Partners's Edwards Lifesciences position peaked at $25.1M in Q4 2021.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on NS Partners's 13F filing for Q1 2026, filed 11 May 2026.